EMEA-000056-PIP03-10-M02

Key facts

Invented name
Avastin
Active substance
bevacizumab
Therapeutic area
Oncology
Decision number
P/0005/2014
PIP number
EMEA-000056-PIP03-10-M02
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of high-grade glioma
Route(s) of administration
Intravenous use
Contact for public enquiries
Roche Registration Ltd
United Kingdom
E-mail: info.paediatrics@roche.com
Tel. +41 616879411
Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-000056-PIP03-10-M02
Compliance opinion date
13/11/2015
Compliance outcome
positive

Decision

How useful was this page?

Add your rating